# Childhood Obesity: A Multisystem Challenge Linking Hypertension, NAFLD, and Sleep Apnea

**Authors:** Martina Montagnana, Elisa Danese, Sara Bonafini, Cristiano Fava

PMC · DOI: 10.3390/medsci14010070 · Medical Sciences · 2026-02-04

## TL;DR

Childhood obesity is linked to hypertension, fatty liver disease, and sleep apnea, requiring early diagnosis and treatment to prevent long-term health issues.

## Contribution

This review synthesizes current evidence on the multisystem health impacts of childhood obesity and highlights pediatric-specific diagnostic and therapeutic approaches.

## Key findings

- Childhood obesity is strongly associated with hypertension, non-alcoholic fatty liver disease, and obstructive sleep apnea.
- Abdominal obesity, measured by waist circumference, is a better predictor of cardiometabolic risk than BMI in children.
- Integrated therapeutic strategies and new pharmacological options are emerging for treating pediatric obesity.

## Abstract

Childhood overweight and obesity represent a major global public health emergency, with a steadily increasing prevalence over recent decades in both developed and developing countries. Approximately one fifth of children and adolescents are overweight or obese, with marked differences across ethnic groups and geographical areas. Accurate estimation of this condition is complicated by the lack of a unique and universally accepted definition of childhood obesity, which is based on different anthropometric criteria. Although body mass index (BMI) remains the most widely used tool, growing evidence indicates that abdominal obesity, assessed by waist circumference and waist-to-height ratio, is a better predictor of cardiometabolic risk, even in children with a normal BMI. Childhood obesity is associated with several comorbidities, including arterial hypertension, non-alcoholic fatty liver disease (NAFLD) and obstructive sleep apnea syndrome (OSAS). Early diagnosis and an integrated therapeutic approach are essential to reduce the risk of long-term complications. Although lifestyle modifications remain the cornerstone of treatment, new pharmacological options for pediatric obesity have been approved in recent years. This narrative review explores the impact of childhood obesity on the early development of hypertension, NAFLD, and OSAS, emphasizing the implications that can already be observed during childhood and adolescence. It examines the association between pediatric obesity and these conditions by synthesizing current epidemiological evidence, describing the underlying pathophysiological mechanisms linking excess adiposity to disease onset, and reviewing pediatric-specific diagnostic criteria as well as preventive and therapeutic strategies.

## Full-text entities

- **Genes:** GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, AP2B1 (adaptor related protein complex 2 subunit beta 1) [NCBI Gene 163] {aka ADTB2, AP105B, AP2-BETA, CLAPB1}, FFAR4 (free fatty acid receptor 4) [NCBI Gene 338557] {aka BMIQ10, GPR120, GPR129, GT01, O3FAR1, OB10Q}, TM6SF2 (transmembrane 6 superfamily member 2) [NCBI Gene 53345], CFD (complement factor D) [NCBI Gene 1675] {aka ADIPSIN, ADN, DF, PFD}, LPIN1 (lipin 1) [NCBI Gene 23175] {aka PAP1}, ACE (angiotensin I converting enzyme) [NCBI Gene 1636] {aka ACE1, CD143, DCP, DCP1}, PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, ADIPOQ (adiponectin, C1Q and collagen domain containing) [NCBI Gene 9370] {aka ACDC, ACRP30, ADIPQTL1, ADPN, APM-1, APM1}, ACE2 (angiotensin converting enzyme 2) [NCBI Gene 59272] {aka ACEH}, REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}, LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, SOD2 (superoxide dismutase 2) [NCBI Gene 6648] {aka GC1, GClnc1, IPO-B, IPOB, MNSOD, MVCD6}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, NAMPT (nicotinamide phosphoribosyltransferase) [NCBI Gene 10135] {aka 1110035O14Rik, PBEF, PBEF1, VF, VISFATIN}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, PNPLA3 (patatin like domain 3, 1-acylglycerol-3-phosphate O-acyltransferase) [NCBI Gene 80339] {aka ADPN, C22orf20, iPLA(2)epsilon}, RETN (resistin) [NCBI Gene 56729] {aka ADSF, FIZZ3, RENT, RETN1, RSTN, XCP1}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, GCG (glucagon) [NCBI Gene 2641] {aka GLP-1, GLP1, GLP2, GRPP}, KLF6 (KLF transcription factor 6) [NCBI Gene 1316] {aka BCD1, CBA1, COPEB, CPBP, GBF, PAC1}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}
- **Diseases:** diarrhea (MESH:D003967), Overweight (MESH:D050177), GLA (MESH:D017093), cardiac damage (MESH:D006331), cholecystitis (MESH:D002764), vitamin D deficiency (MESH:D014808), hepatic disease (MESH:D056486), nausea (MESH:D009325), NASH (MESH:D005235), Obese (MESH:D009765), adiposity (MESH:D018205), LVM (MESH:D018487), fatty liver (MESH:D005234), T2DM (MESH:D003924), OSAS (MESH:D020181), chronic diseases (MESH:D002908), hypoxemia (MESH:D000860), vomiting (MESH:D014839), snoring (MESH:D012913), visceral adiposity (MESH:D007418), Wilson disease (MESH:D006527), Sleep Apnea (MESH:D012891), tonsil hypertrophy (MESH:D014069), abdominal obesity (MESH:D056128), cholelithiasis (MESH:D002769), airway obstruction (MESH:D000402), viral hepatitis (MESH:D014777), mitochondrial dysfunction (MESH:D028361), arterial hypertension (MESH:D000081029), apnea (MESH:D001049), High Blood Pressure (MESH:D006973), daytime sleepiness (MESH:D012893), POS (MESH:D011085), dyslipidemia (MESH:D050171), respiratory disease (MESH:D012140), hyperinsulinemia (MESH:D006946), cirrhosis (MESH:D005355), end-stage liver disease (MESH:D058625), gallbladder disease (MESH:D005705), Excess (MESH:D006970), injury to (MESH:D014947), respiratory tract infections (MESH:D012141), autoimmune liver disease (MESH:D008107), portal hypertension (MESH:D006975), inflammation (MESH:D007249), upper-airway collapse (MESH:D001261), WC (MESH:D064250), OSA (MESH:C535586), asthma (MESH:D001249), acute pancreatitis (MESH:D010195), insulin resistance (MESH:D007333), vascular damage (MESH:D057772), alpha1-antitrypsin deficiency (MESH:D019896), prediabetes (MESH:D011236), gastrointestinal side effects (MESH:D064420), abdominal pain (MESH:D015746), weight loss (MESH:D015431), Adenoid hypertrophy (MESH:D006984), diabetes (MESH:D003920), COVID-19 (MESH:D000086382)
- **Chemicals:** free fatty acids (MESH:D005230), exenatide (MESH:D000077270), lipid (MESH:D008055), metformin (MESH:D008687), fructose (MESH:D005632), phentermine (MESH:D010645), calcium (MESH:D002118), glucose (MESH:D005947), creatinine (MESH:D003404), NO (MESH:D009569), magnesium (MESH:D008274), alcohol (MESH:D000438), norepinephrine (MESH:D009638), oxygen (MESH:D010100), orlistat (MESH:D000077403), sodium (MESH:D012964), sugar (MESH:D000073893), Vitamin D (MESH:D014807), unsaturated long-chain free fatty acids (-), epinephrine (MESH:D004837), cortisone (MESH:D003348), fatty acid (MESH:D005227), triglyceride (MESH:D014280), aldosterone (MESH:D000450), corticosterone (MESH:D003345), cortisol (MESH:D006854), prostaglandins (MESH:D011453), leukotrienes (MESH:D015289)
- **Species:** Bifidobacterium adolescentis (species) [taxon 1680], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** C>T, 148M, isoleucine-to-methionine, rs13412852, rs3750861, G>A, glutamate by lysine at residue 167, rs4880, rs5852926, R270H

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12922023/full.md

## References

161 references — full list in the complete paper: https://tomesphere.com/paper/PMC12922023/full.md

---
Source: https://tomesphere.com/paper/PMC12922023